A5085537336- Glioma Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- Brain Metastases and Treatment
- Histone Deacetylase Inhibitors Research
- MicroRNA in disease regulation
- Neurogenesis and neuroplasticity mechanisms
- Cancer Treatment and Pharmacology
- RNA Interference and Gene Delivery
- Chronic Myeloid Leukemia Treatments
- Multiple Myeloma Research and Treatments
- Angiogenesis and VEGF in Cancer
- Cancer Mechanisms and Therapy
- Cancer Cells and Metastasis
- Vascular Malformations Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Neuroblastoma Research and Treatments
- Acute Myeloid Leukemia Research
- Cancer Research and Treatments
- Lung Cancer Treatments and Mutations
- MRI in cancer diagnosis
- Nanoplatforms for cancer theranostics
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cerebrospinal fluid and hydrocephalus
- Spinal Dysraphism and Malformations
- Meningioma and schwannoma management
Siriraj Hospital
2015-2025
Mahidol University
2015-2025
National Nanotechnology Center
2015-2024
Duke Medical Center
2004-2023
Duke University Hospital
2004-2023
National Science and Technology Development Agency
2017
Cleveland Clinic
2010
Duke University
2004-2008
UPMC Hillman Cancer Center
2006-2007
CASI Pharmaceuticals (United States)
2007
Purpose The prognosis for patients with recurrent glioblastoma multiforme is poor, a median survival of 3 to 6 months. We performed phase II trial bevacizumab, monoclonal antibody vascular endothelial growth factor, in combination irinotecan. Patients and Methods This included two cohorts patients. initial cohort, comprising 23 patients, received bevacizumab at 10 mg/kg plus irinotecan every 2 weeks. dose was based on the patient's anticonvulsant: taking enzyme-inducing antiepileptic drugs...
Malignant gliomas are highly lethal cancers dependent on angiogenesis. Critical tumor subpopulations within share characteristics with neural stem cells. We examined the potential of cell-like glioma cells (SCLGC) to support SCLGC isolated from human glioblastoma biopsy specimens and xenografts potently generated tumors when implanted into brains immunocompromised mice, whereas non-SCLGC only a few formed secondary xenotransplanted. Tumors derived were morphologically distinguishable...
Abstract Purpose: Recurrent grade III-IV gliomas have a dismal prognosis with minimal improvements in survival seen following currently available salvage therapy. This study was conducted to determine if the combination of novel antiangiogenic therapy, bevacizumab, and cytotoxic agent, irinotecan, is safe effective for patients recurrent glioma. Experimental Design: We phase II trial bevacizumab irinotecan adults Patients evidence intracranial hemorrhage on initial brain magnetic resonance...
Malignant gliomas are lethal cancers that display striking cellular heterogeneity. A highly tumorigenic glioma tumor subpopulation, termed cancer stem cells or tumor-initiating cells, promotes therapeutic resistance and angiogenesis. Therefore, targeting may improve patient survival. We interrogated the role of a neuronal cell adhesion molecule, L1CAM, in as L1CAM regulates brain development is expressed gliomas. L1CAM(+) CD133(+) cosegregated gliomas, levels were higher than normal neural...
We performed a phase II study to evaluate the combination of imatinib mesylate, an adenosine triphosphate mimetic, tyrosine kinase inhibitor, plus hydroxyurea, ribonucleotide reductase in patients with recurrent glioblastoma multiforme (GBM).Patients GBM at any recurrence received mesylate hydroxyurea (500 mg twice day) orally on continuous, daily schedule. The dose was 500 day for enzyme-inducing antiepileptic drugs (EIAEDs) and 400 once those not EIAEDs. Assessments were every 28 days....
The combination of a vascular endothelial growth factor (VEGF) -neutralizing antibody, bevacizumab, and irinotecan is associated with high radiographic response rates improved survival outcomes in patients recurrent malignant gliomas. aim these retrospective studies was to evaluate tumor vascularity expression components the VEGF pathway hypoxic responses as predictive markers for benefit from bevacizumab therapy.In phase II trial, 60 astrocytomas were treated irinotecan. Tumor specimens...
Vascular endothelial growth factor (VEGF) and epidermal receptor (EGFR) signaling are established contributors to malignant glioma (MG) biology. We, therefore, evaluated bevacizumab, a humanized anti-VEGF monoclonal antibody, in combination with the EGFR tyrosine kinase inhibitor erlotinib, this phase 2 study for recurrent MG patients (www.ClinicalTrials.gov, NCT00671970). Fifty-seven (n = 25, glioblastoma [GBM]; n 32, anaplastic [AG]) were enrolled. The primary endpoint was 6-month...
We evaluated bevacizumab with metronomic etoposide among recurrent malignant glioma patients in a phase 2, open-label trial. A total of59 patients, including 27 glioblastoma (GBM) and 32 grade 3 glioma, received 10 mg kg−1 biweekly 50 m−2 daily for 21 consecutive days each month. The primary end point was 6-month progression-free survival, secondary points included safety overall survival. Vascular endothelial growth factor (VEGF), VEGFR-2, carbonic anhydrase 9 (CA9) hypoxia-inducible...
Abstract Purpose: To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of gefitinib, a receptor tyrosine kinase inhibitor epidermal growth factor receptor, plus sirolimus, an mammalian target rapamycin, among patients with recurrent malignant glioma. Patients Methods: Gefitinib sirolimus were administered on continuous daily dosing schedule at levels that escalated in successive cohorts glioma any recurrence who stratified based concurrent use CYP3A-inducing...
Abstract Purpose: Although patients with newly diagnosed WHO grade 3 malignant glioma have a more favorable prognosis than those 4 glioma, salvage therapies following recurrence offer essentially palliative benefit. We did phase II trial of bevacizumab, monoclonal antibody to vascular endothelial growth factor, in combination irinotecan for recurrent glioma. Experimental Design: Upon documentation adequate safety among an initial cohort nine treated bevacizumab (10 mg/kg) and every 14 days,...
Abstract Transforming growth factor-β (TGF-β) is a multifunctional cytokine that promotes malignant glioma invasion, angiogenesis, and immunosuppression. Antisense oligonucleotide suppression of TGF-β2 ligand expression has shown promise in preclinical clinical studies but at least two ligands mediate the effects TGF-β gliomas. Therefore, we examined SB-431542, novel, small molecule inhibitor type I receptor, on panel human cell lines. SB-431542 blocked phosphorylation nuclear translocation...
Bevacizumab improves outcome for most recurrent glioblastoma patients, but the duration of benefit is limited and survival after initial bevacizumab progression poor. We evaluated continuation beyond among patients as it a common, yet unsupported practice in some countries. analysed all (n=99) who received subsequent therapy on one five consecutive, single-arm, phase II clinical trials evaluating regimens glioblastoma. Of note, contained similar eligibility, treatment assessment criteria,...
Abstract Purpose: Primary central nervous system (CNS) tumors represent a diverse group of tumor types with heterogeneous molecular mechanisms that underlie their formation and maintenance. CNS depend on angiogenesis often display increased activity ErbB-associated pathways. Current nonspecific therapies frequently have poor efficacy in many these types, so there is pressing need for the development novel targeted therapies. Experimental Design: ZD6474 novel, orally available low weight...
Abstract Oligodendrogliomas are defined at the molecular level by presence of an IDH mutation and codeletion chromosomal arms 1p 19q. In past, case reports small studies described gliomas with sarcomatous features arising from oligodendrogliomas, so called oligosarcomas. Here, we report a series 24 IDH-mutant oligosarcomas 23 patients forming distinct methylation class. The tumors were recurrences prior oligodendrogliomas or developed de novo. Precursor 12 histologically molecularly...